Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Elamipretide for Sale > SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%
SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99% buy - large image1
SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99% buy - image1
SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99% buy - image2
SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99% buy - image3
SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99% buy - image4
SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99% buy - image5
SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99% buy - image6

SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%

COA 97 Inquiries

Unit Price:

$65/UNIT FOB

Get Latest Price
CAS No.:

736992-21-5

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Chinese mainland

Brand:

any

Packaging:

10mg*10vials/50mg*10vials

Price valid (until):

2026-09-18

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Semag lutide,Tirzepatide,Retatrutide,raw material,GHK-CU,TB500(Thymosin B4 AceTate)

  • Product Description

  • Seller Information

  • History Price

  • Inquiry History

  • Description

    Name:Rain

    Whatsapp:+852 69948372

    Email:rain@anymang.cn

    Triple Agonist Design :

    GLP-1 receptor: Retatrutide delays gastric emptying, suppress appetite, and promote secretion.

    GIP receptor: Retatrutide enhances sensitivity and regulate central satiety signals.

    Glucagon receptor (GCGR): Retatrutide activates liver energy metabolism, promote lipolysis and glycogenolysis, and increase basal metabolic rate.

    The triple synergistic effect increases energy consumption while reducing energy intake, significantly improving weight loss effects.


    Mechanism of Action and Molecular Structure of Retatrutide:

    1)Triple Agonist Design
    - GLP-1 receptor: Retatrutide delays gastric emptying, suppress appetite, and promote secretion.
    - GIP receptor: Retatrutide enhances insulin sensitivity and regulate central satiety signals.
    - Glucagon receptor (GCGR): Retatrutide activates liver energy metabolism, promote lipolysis and glycogenolysis, and increase basal metabolic rate.
    The triple synergistic effect increases energy consumption while reducing energy intake, significantly improving weight loss effects.

    2) Structural Optimization
    - Based on the GIP skeleton modification, non-natural amino acids (such as α-methylleucine at position 13) are introduced to enhance receptor affinity.
    - The half-life is extended to 7 days through fatty acid side chain modification

    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 1
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 2
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 3
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 4
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 5
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 6
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 7
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 8
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 9
    Shop SS-31 30*mg 15+yeras API, Raw, Peptide factory supplier 99%-Detailed Image 10
    ECHEMI Editorial Reference
    Elamipretide has been used in trials studying the treatment of Leber's Hereditary Optic Neuropathy.
    Elamipretide, also known as MTP 131, is a mitochondria-targeted peptide antioxidant. Elamipretide decreases inflammation and protect against a variety of neurological illnesses. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by Nutrient Excess in INS1 β-cells.
    Elamipretide Synthetic is a single, non-glycosylated polypeptide chain containing 4 amino acids, having a molecular mass of 640 Dalton and a Molecular formula of C32H49N9O5 .

    Certificates

    Basic Info
    Product Name:

    Elamipretide

    Other Name:

    D-Arginyl-2,6-diMethyl-L-tyrosyl-L-lysyl-L-phenylalaninaMide;Elamipretide;L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-;Elamipretide (TFA salt);SS-31;MTP-131;BENDAVIA;Bendavia);Elamipretide (SS-31;ELAMIPRETIDE, >99%

    CAS No.:

    736992-21-5

    Molecular Formula:

    C32H49N9O5

    InChIKeys:

    SFVLTCAESLKEHH-WKAQUBQDSA-N

    Molecular Weight:

    639.79

    Exact Mass:

    639.38566570

    EC Number:

    205-858-1

    UNII:

    87GWG91S09

    DSSTox ID:

    DTXSID50471988

    Color/Form:

    White to Off-White

    Characteristics
    Density:

    1.34±0.1 g/cm3(Predicted)

    PKA:

    10.10±0.25(Predicted)

    Research
    Class:

    Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)

    Status:

    FDA-approved (Forzinity) — Accelerated Approval 2025

    Mechanism:

    A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.

    Activity note:

    SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.

    Source:

    Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI

    Clinical Development:

    NCT03098797; NCT02814097; NCT02976038; NCT03354065

    FDA:

    Forzinity (approved 2025-09-19)

    References
    ChEMBL:

    CHEMBL3833370

    DrugBank:

    DB11981

    KEGG DRUG:

    D10925

    PubChem:

    PubChem

    Disclaimer:

    Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

    Hazard Identification

    Classification of the substance or mixture

    no data available

    GHS label elements, including precautionary statements

    Pictogram(s) no data available
    Signal word

    no data available

    Hazard statement(s)

    no data available

    Precautionary statement(s)
    Prevention

    no data available

    Response

    no data available

    Storage

    no data available

    Disposal

    no data available

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Semag lutide,Tirzepatide,Retatrutide,raw material,GHK-CU,TB500(Thymosin B4 AceTate)

    Location:

    Room 1002-C3973, No. 80, Yongtai Modaonan Street, Yongping Subdistrict, Baiyun District, Guangzhou City

    Payment Terms:

    TT against copy of documents,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    45

    Year of Establishment:

    2026

    Anymang is a US-based trading company dedicated to the global supply and formulation of high-quality cosmetic raw materials, with a core focus on peptide ingredients. Committed to bridging premium suppliers and beauty manufacturers worldwide, we deliver pure, stable, and efficacious peptides—including anti-aging, brightening, and firming peptides—alongside a full spectrum of cosmetic actives and custom formulation solutions. With rigorous quality control and compliance with US safety standards, we ensure consistent batch quality and reliable delivery. Our experienced team provides professional technical support and tailored services to help clients develop competitive skincare and personal care products. Trusted by partners across the globe, Anymang stands as your dependable partner for innovative, high-performance cosmetic raw materials and peptide formulations.

  • Weekly Price

    The chart shows the price trend of the product in the past 12 months.

  • Inquiry History
    97 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    SS-31 (Elamipretide MTP-131) CAS 736992-21-5 99% White Powder XO

    10  Oct 22, 2023
    Canada

    SS-31 (Elamipretide MTP-131) CAS 736992-21-5 99% White Powder XO

    Sep 28, 2023
    United States

    SS-31

    500 MG Feb 20, 2026
    Philippines

    Elamipretide

    100 MG Mar 17, 2026
    Philippines

    Elamipretide / SS-31

    5 G Mar 16, 2026
    Kazakstan

    SS-31

    500 MG May 22, 2026
    Australia

    SS-31

    30 MG Aug 24, 2026
    Brazil

    SS-31 Lyophilized Powder

    0.1 G Jul 9, 2026
    India

    Elamipretide

    1 G Jun 23, 2026
    France

    Elamipretide

    3 G Jun 19, 2026
    United States

    Elamipretide

    5 G Jun 18, 2026
    Netherlands

    ss31

    12 G Jun 8, 2026
    United States

    ss-31

    10 G May 19, 2026
    United States

    99% lypholized ss-31 Elamipretide 10mg and 20mg vials

    10 MT May 16, 2026
    United States

    Elamipretide

    200 MG Apr 27, 2026
    United States

    SS-31

    1 KG Apr 24, 2026
    United States

    ss-31

    500 MG Apr 13, 2026
    United States

    SS-31

    1 G Mar 23, 2026
    Canada

    Ss-31

    10 MT Mar 21, 2026
    United States

    SS-31 (Elamipretide)

    10 MT Mar 10, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.